Selvita wants to become one of the ten largest global preclinical CROs (Contract Research Organization) within the next few years, said president Bogusław Sieczkowski. The company’s goal is further organic growth at a rate of approximately 30% a year (in terms of revenues) and acquisitions of domestic and European entities. Selvita wants to make the first acquisition next year, Sieczkowski added. Today, the company’s shares debuted on the main market of the Warsaw Stock Exchange.
“Our future is the global market. This is a very ambitious task, but when we look at how much good has been extracted from the Polish market in the last 12 years, we believe that CEE is a place where a really big player can be built. In the medium term, it will be able to reach the top ten preclinical CROs in the world,” Sieczkowski argued.
The company is interested in domestic and foreign companies that would allow it to achieve its business objectives: increasing the scale of operations and complementing its portfolio of offered services. The president pointed out that Central and Eastern Europe is a natural takeover area.